However, since the inhibitory effect of the NADPH oxidase system through activation of PPARα has been observed in studies other than studies using metabolic disorder models [34,35], pemafibrate may have a direct inhibitory effect on the production of ROS via inactivation of the NADPH oxidase system, independent of metabolic disorders, including lipid metabolism. The gene discussed is PPARA; the disease is metabolic disease.